The company has made new investments, which will allow it to increase its production capacity fivefold in one of its microbial manufacturing lines. At present, the company has more than 350 workers, collaborates with more than twenty-five international clients and its facilities total 10,500 m2 after the latest remodelling.
3P Biopharmaceuticals has completed its second line of protein manufacturing from bacteria and yeast with the installation of a 500-litre stainless steel bioreactor with fermentation technology. According to the company’s announcement on Wednesday, this installation completes the three existing fermentation lines that manufacture drugs from microbial cells and yeast. With this new investment, the company now has capacities of 10 litres, 100 litres, 500 litres and 1,000 litres for microbial production.
The new bioreactor will allow the Navarra-based biotech company to “multiply by five” the production capacity in one of its three microbial manufacturing lines.
In 2022, 3P Biopharmaceuticals celebrated its fifteenth anniversary and closed the year with a turnover of more than 42 million euros and a growth of 22%. Today, the company has more than 350 employees, collaborates with more than twenty-five international clients and its facilities now cover a total of 10,500 m2.